Abstract
Introduction:
Linear morphea is an inflammatory condition that is often treated with systemic glucocorticoids and methotrexate, with mycophenolate mofetil being used as an alternative agent. However, there are few published reports on beneficial effect of abatacept for refractory disease. We present a case of a woman in her 30s who presented with linear morphea on her scalp, with a notable response following the addition of subcutaneous abatacept.
Methods:
Computational analysis was performed comparing the immune cell scores of skin biopsies from five morphea skin biopsies from three additional unique patients and 15 healthy control skin biopsies. Value of p < 0.05 was considered statistically significant.
Results:
Immune cell scores demonstrated a statistically significant enrichment of activated CD4 memory T cells, M1 macrophages, monocytes, and memory B cells comparing skin biopsies of morphea versus healthy controls (p < 0.05 for all).
Discussion:
Abatacept may be considered for recalcitrant cases of morphea. Our computational analysis supports a well-designed study is needed to assess abatacept as first-line therapy.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
